Xenetic Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary

• Xenetic Biosciences Inc XBIO.OQ reported a quarterly adjusted loss of 68 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -77 cents. The lone analyst forecast for the quarter was for a loss of 20 cents per share.

• Revenue fell 3.6% to $648.00 thousand from a year ago; analysts expected $230.00 thousand.

• Xenetic Biosciences Inc's reported EPS for the quarter was a loss of 68 cents​.

• The company reported a quarterly loss of $1.05 million.

• Xenetic Biosciences Inc shares had fallen by 13.3% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

This summary was machine generated from LSEG data March 19 at 09:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)